1. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC
   Julia Esperanza Torres-Mena et al, 2018, Dig Dis Sci CrossRef
2. Biostatistics mining associated method identifies AKR1B10 enhancing hepatocellular carcinoma cell growth and degenerated by miR-383-5p
   Junqing Wang et al, 2018, Sci Rep CrossRef
3. Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma
   Jung-Jyh Hung et al, 2018, Thorac Cancer CrossRef
4. Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma
   Johanna DiStefano et al, 2019, Cancers CrossRef
5. A Large‐Scale Multicenter Study Validates Aldo‐Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma
   Xu Ye et al, 2019, Hepatology CrossRef
6. Overexpression of Cullin7 is associated with hepatocellular carcinoma progression and pathogenesis
   Jun An et al, 2017, BMC Cancer CrossRef
7. A Multi-classifier Model to Identify Mitochondrial Respiratory Gene Signatures in Human Cancer
   Saurav Mallik et al, 2019 CrossRef
8. Integrated analysis of the impact of age on genetic and clinical aspects of hepatocellular carcinoma
   Manar Atyah et al, 2018, Aging CrossRef
9. Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers
   Rongqiang Liu et al, 2021 CrossRef
10. AKR1B10 inhibits the proliferation and migration of gastric cancer via regulating epithelial-mesenchymal transition
    Xinyu Shao et al, 2021, Aging CrossRef
11. Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma
    Tiangen Wu et al, 2021, Molecular Therapy - Oncolytics CrossRef
12. Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis
    Zixiang Wang et al, 2022, PLoS ONE CrossRef
13. Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review
    Endrit Shahini et al, 2023, IJMS CrossRef
14. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma
    Chenglin Xie et al, 2023, J Gastroenterol CrossRef
15. Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma
    Ziran Wang et al, 2024, JHC CrossRef